Qi-Shen-Yi-Qi Dripping Pills for the secondary prevention of myocardial infarction: A randomised clinical trial

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Shang, Hongcai ^a   Zhang, Junhua ^a   Yao, Chen ^b   Liu, Baoyan ^c   Gao, Xiumei ^a   Ren, Ming ^a   Cao, Hongbao ^a   Dai, Guohua ^d   Weng, Weiliang ^e   Zhu, Sainan ^b   Wang, Hui ^a   Xu, Hongjuan ^a   Zhang, Boli ^a  

^a TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^d AFFILIATED HOSPITAL OF SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^e XIYUAN HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CHINESE DRUG; QI SHEN YI QI; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN HEMORRHAGE; CHINESE MEDICINE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DUODENOGASTRIC REFLUX; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; STOMACH PAIN; SUBCUTANEOUS HEMORRHAGE; TREATMENT DURATION;

EID: 84881512793     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/738391     Document Type: Article

References (31)

1. World Health Organization, The top ten causes of death. Fact sheet, no. 310, 2008
2. White H. D., Chew D. P., Acute myocardial infarction. The Lancet 2008 372 9638 570 584 2-s2.0-49449104281 10.1016/S0140-6736(08)61237-4
3. He J., Gu D., Wu X., Reynolds K., Duan X., Yao C., Wang J., Chen C.-S., Chen J., Wildman R. P., Klag M. J., Whelton P. K., Major causes of death among men and women in China. New England Journal of Medicine 2005 353 11 1124 1134 2-s2.0-24944542337 10.1056/NEJMsa050467 (Pubitemid 41317435)
4. Sanderson J. E., Mayosi B., Yusuf S., Reddy S., Hu S., Chen Z., Timmis A., Global burden of cardiovascular disease. Heart 2007 93 10 1175 2-s2.0-34848820598 10.1136/hrt.2007.131060 (Pubitemid 47492896)
5. Moher M., Evidence of the effectiveness of interventions for secondary prevention and treatment of coronary heart disease in primary care-a review of the literature. NHS Executive, Anglia and Oxford Regional Health Authority, Oxford, UK, 1995
6. Xiang Y.-Z., Xia Y., Gao X.-M., Shang H.-C., Kang L.-Y., Zhang B.-L., Platelet activation, and antiplatelet targets and agents: current and novel strategies. Drugs 2008 68 12 1647 1664 2-s2.0-49249127272 10.2165/00003495- 200868120-00004
7. Baigent C., Sudlow C., Collins R., Peto R., Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal 2002 324 7329 71 86 2-s2.0-0037065502 (Pubitemid 34073138)
8. Antithrombotic Trialists' Collaboration, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet 2009 373 9678 1849 1860 2-s2.0-65849268320 10.1016/S0140-6736(09)60503-1
9. García Rodríguez L. A., Hernández-Díaz S., de Abajo F. J., Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. British Journal of Clinical Pharmacology 2001 52 563 571
10. Derry S., Loke Y. K., Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. British Medical Journal 2000 321 7270 1183 1187 2-s2.0-0034638656
11. De Berardis G., Lucisano G., D'Ettorre A., Pellegrini F., Lepore V., Tognoni G., Nicolucci A., Association of aspirin use with major bleeding in patients with and without diabetes. Journal of the American Medical Association 2012 307 21 2286 2294
12. Hovens M. M. C., Snoep J. D., Eikenboom J. C. J., van der Bom J. G., Mertens B. J. A., Huisman M. V., Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. American Heart Journal 2007 153 2 175 181 2-s2.0-33846235920 10.1016/j.ahj.2006.10.040 (Pubitemid 46096871)
13. Snoep J. D., Hovens M. M. C., Eikenboom J. C. J., Van Der Bom J. G., Huisman M. V., Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Archives of Internal Medicine 2007 167 15 1593 1599 2-s2.0-34447503098 10.1001/archinte.167.15.1593 (Pubitemid 47280339)
14. Krasopoulos G., Brister S. J., Beattie W. S., Buchanan M. R., Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. British Medical Journal 2008 336 7637 195 198 2-s2.0-38949119325 10.1136/bmj.39430.529549.BE (Pubitemid 351212675)
15. Xiang Y.-Z., Kang L.-Y., Gao X.-M., Shang H.-C., Zhang J.-H., Zhang B.-L., Strategies for antiplatelet targets and agents. Thrombosis Research 2008 123 1 35 49 2-s2.0-54049147727 10.1016/j.thromres.2008.05.003
16. Yunfei L., Haibin Q., Yiyu C., Identification of major constituents in the traditional Chinese medicine "QI-SHEN-YI-QI" dropping pill by high-performance liquid chromatography coupled with diode array detection-electrospray ionization tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2008 47 2 407 412 2-s2.0-42749083555 10.1016/j.jpba.2007.12.037
17. Wang Y., Wang J., Guo L., Gao X., Antiplatelet effects of qishen yiqi dropping pill in platelets aggregation in hyperlipidemic rabbits. Evidence-Based Complementary and Alternative Medicine 2012 2012 5 205451 10.1155/2012/205451
18. Chen J., Qu D. Z., Wang R. Y., Evaluation of Qishenyiqi Dripping Pills for aspirin resistance in patients with coronary heart disease. Chinese Traditional and Herbal Drugs 2008 39 96 97
19. Alpert J. S., Thygesen K., Antman E., Bassand J. P., Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Journal of the American College of Cardiology 2000 36 959 969 2-s2.0-0035282186
20. Xiang Y. Z., Shang H. C., Zhang B. L., Secondary prevention of myocardial infarction and applicable prospect of traditional Chinese medicine. Medical Recapitulate 2007 13 263 265
21. Sanz G., Fuster V., Kravis M.-J., Kravis H. R., Gorlin R., Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nature Clinical Practice Cardiovascular Medicine 2009 6 2 101 110 2-s2.0-59549102578 10.1038/ ncpcardio1419
22. Wald N. J., Law M. R., The Indian Polycap Study (TIPS). The Lancet 2009 374 781
23. Wald N. J., Law M. R., A strategy to reduce cardiovascular disease by more than 80%. British Medical Journal 2003 326 7404 1419 1423 2-s2.0-0038165393 (Pubitemid 36776151)
24. Yusuf S., Pais P., Afzal R., Xavier D., Teo K., Eikelboom J., Sigamani A., Mohan V., Gupta R., Thomas N., Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. The Lancet 2009 373 1341 1351
25. Soliman E. Z., Mendis S., Dissanayake W. P., Somasundaram N. P., Gunaratne P. S., Jayasingne I. K., Furberg C. D., A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials 2011 12, article 3 2-s2.0-78650762207 10.1186/1745-6215-12- 3
26. Gu J., Yuan G., Zhu Y., Xu X., Computational pharmacological studies on cardiovascular disease by Qishenyiqi Diwan. Science in China B 2009 39 1415 1423
27. Lin S. Q., Wei X. H., Huang P., Liu Y. Y., QiShenYiQi Pills prevents cardiac ischemia-reperfusion injury via energy modulation. International Journal of Cardiology 2012 10.1016/j.ijcard.2012.10.042
28. Hong C., Wang Y., Lou J., Liu Q., Qu H., Cheng Y., Analysis of myocardial proteomic alteration after Qishenyiqi formula treatment in acute infarcted rat hearts. Zhongguo Zhongyao Zazhi 2009 34 8 1018 1021 2-s2.0-67650523662
29. Du W. X., Zhu M. D., Feng L. M., Song Q. G., Wei Y., Ma P., Liu C. Y., Liu M., Intervention effect of Qishenyiqi dripping pills on early ventricular remodeling after acute myocardial infarction. Chinese Journal of Evidence-Based Cardiovascular Medicine 2008 28 41 43
30. Yan F. F., Liu Y., Liu Y. F., Zhao Y. X., Effects of Qishenyiqi Dripping pills on high sensitivity C reactive protein in experimental atherosclerosis rabbits. Shanghai Journal of Traditional Chinese Medicine 2007 41 59 60
31. Yan F. F., Liu Y., Liu Y. F., Zhao Y. X., Effect of Qishenyiqi dripping pills on histology of experimental atherosclerotic plaque. Journal of Nanjing University of Traditional Chinese Medicine 2007 23 295 297